By: B. Neyns MD, PhD
At ESMO 2023, important advances in the (neo-)adjuvant treatment for patients with cutaneous melanoma were presented, including an exploratory analysis of the SWOG S1801 trial and the results from the phase II Keynote-942 trial. Furthermore, there were some interesting updates on the progress in the treatment of metastatic uveal melanoma and some of the emerging new cellular therapies for metastatic melanoma.
(BELG J MED ONCOL 2023;17(8):281–5)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
